The two hundred million dollar dash

Macht, Joshua
September 1997
Inc.;1997 Inc. Technology 3, Vol. 19 Issue 13, p48
Discusses how Isis Pharmaceuticals became digital in order to compete in the competitive pharmaceutical industry. The deployment of the company's intranet as one of the many technological tricks that Isis does to meet the rigorous and costly bureaucratic demands of drug development and approval; Isis as on track to be first to market with a class of drugs known as antisense; The electronic new drug application to the US Food & Drug Administration on a single CD-ROM. INSET: No mistakes about it..


Related Articles

  • Isis and Carlsbad forging biotech partnership. Fikes, Bradley J. // San Diego Business Journal;5/22/95, Vol. 16 Issue 21, p36 

    Features Isis Pharmaceuticals Inc. Incentives received from the city of Carlsbad; Foundation history; Number of employees; Research on products; Business partners.

  • Isis receives allowance for patent on ISIS 2922.  // Ophthalmology Times;4/24/95, Vol. 20 Issue 17, p6 

    Reports on an allowance given to Isis Pharmaceuticals for a patent on its ISIS 2922 antisense compound which inhibits the cytomegalovirus.

  • New drug tested.  // San Diego Business Journal;1/29/96, Vol. 17 Issue 5, p27 

    Reports that Isis Pharmaceuticals has started Phase I human clinical trials of a class of anti-cancer drug.

  • Isis starts drug trials for anti-inflammatory.  // San Diego Business Journal;8/7/95, Vol. 16 Issue 32, p6 

    Reports that Isis Pharmaceuticals Inc. has begun Phase II clinical trials of an anti-inflammatory drug, Isis 2302. Collaboration between Isis Pharmaceuticals Inc. and Boehringer Ingelheim.

  • Kids' catalogue calls for inserts. Brown, Curtis // Precision Marketing;9/27/2002, Vol. 15 Issue 1, p26 

    Reports that Isis Direct, a direct marketing company in Great Britain, is offering an insert opportunity in its mail order children's clothing catalog.

  • American Diabetes Association.  // BioWorld Today;6/30/2010, Vol. 21 Issue 125, p4 

    The article reports on the release of data from the obesity drug discovery program by Isis Pharmaceuticals Inc. in Carlsbad, California.

  • 'We Want to Control It'.  // BioWorld Today;7/23/2013, Vol. 24 Issue 139, p8 

    The article notes the bright prospects for Isis-ApoCIIIRx by Isis Pharmaceuticals Inc., a drug in the pipeline for patients with severe hypertriglyceridemia.

  • list file. Brown, Curtis // Precision Marketing;12/7/2001, Vol. 14 Issue 11, p31 

    Presents an update on the direct marketing industry as of December 7, 2001. Availability of Letterbox's insert program through Isis Direct; Release of Emap Automotive's list of car and bike enthusiasts through Swetenhams; Decision of global online software store www.swreg.org to release its...

  • ISIS 104838 GETS PROMISING DATA FROM PHASE 2 CLINICAL TRIAL.  // Biotech Business;Mar2004, Vol. 17 Issue 3, p8 

    Focuses on a Phase 2 clinical trial data reported by Isis Pharmaceuticals, Inc. about antisense tumor necrosis factor-alpha inhibitor ASIS 104838.


Read the Article


Sign out of this library

Other Topics